title: Pharmacological and clinical properties of AIMIX® combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate.
authors.affiliation: masaya-mori@ds-pharma.co.jp
authors.forename: Masaya
authors.initials: M
authors.lastname: Mori
authors.forename: Shino
authors.initials: S
authors.lastname: Takahashi
mesh_terms: D017311:Amlodipine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004338:Drug Combinations; D015195:Drug Design; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D000077405:Irbesartan; D013607:Tablets; D013777:Tetrazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D002121:Calcium Channel Blockers; D004338:Drug Combinations; D013607:Tablets; D013777:Tetrazoles; D017311:Amlodipine; D000077405:Irbesartan